- Home
- HTO vs TRVI Comparison
HTO vs TRVI Comparison
Compare HTO & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTO | TRVI |
|---|---|---|
| Founded | 1985 | 2011 |
| Country | United States | United States |
| Employees | 837 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HTO | TRVI |
|---|---|---|
| Price | $66.84 | $18.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $62.00 | $21.55 |
| AVG Volume (30 Days) | 477.0K | ★ 2.7M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.26 | N/A |
| Revenue Next Year | $7.06 | N/A |
| P/E Ratio | $17.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.75 | $6.55 |
| 52 Week High | $66.05 | $20.22 |
Technical Indicators
Market Signals| Indicator | HTO | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 71.56 | 54.05 |
| Support Level | $55.76 | $10.20 |
| Resistance Level | N/A | $20.19 |
| Average True Range (ATR) | 1.34 | 1.25 |
| MACD | 0.06 | -0.13 |
| Stochastic Oscillator | 88.70 | 46.48 |
Price Performance
Historical ComparisonAbout HTO H2O America
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come. Its single reportable segment provides water utility and utility-related services to its customers.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.